home / stock / cue / cue news

CUE News and Press, Cue Biopharma Inc. From 03/01/21

Stock Information
Company Name: Cue Biopharma Inc.
Stock Symbol: CUE
Market: NASDAQ
Website: cuebiopharma.com
Menu
CUE CUE Quote CUE Short CUE News CUE Articles CUE Message Board
Get CUE Alerts

News, Short Squeeze, Breakout and More Instantly...
CUE - Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced t...
CUE - Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos

CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced to...

CUE - Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced to...

CUE - Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development

Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-s...
CUE - NexImmune Proposes Terms For $75 Million IPO

NexImmune has filed to raise $75 million from an IPO of its common stock. The firm is advancing nanoparticle-assisted treatment candidates for various blood and other cancers. Barclays is the lead underwriter and its IPOs have performed in the middle tier over the last 12 months. ...

CUE - Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced to...

CUE - Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022

Cue Biopharma is a clinical-stage biopharmaceutical company developing novel injectables that modulate targeted T-cells. Cue Biopharma has expanded its pipeline to include 7 therapeutics with 1 undergoing clinical trials (CUE-101). CUE-101 is Cue's lead therapeutic halfway through Pha...
CUE - Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced to...

CUE - Cue Biopharma (CUE) Investor Presentation - Slideshow

The following slide deck was published by Cue Biopharma, Inc. in conjunction with this event. For further details see: Cue Biopharma (CUE) Investor Presentation - Slideshow

CUE - Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck

CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that ...
Previous 10 Next 10